Sign in
CompletedPhase 3

Efficacy, Safety and Tolerability of KLU156 in Adults and Children With Uncomplicated P. Falciparum Malaria

Key facts

Who runs it
Novartis Pharmaceuticals
Where
Burkina Faso, Congo - Kinshasa, Côte d’Ivoire, Gabon, Ghana, Kenya, Mali, Niger, Rwanda, Tanzania, Uganda, and Zambia32 sites in 12 countriesChoose a country to see its sites
Status
Completed
Phase
Phase 3
People taking part
1,720 people enrolled
Started
7 Mar 2024
Ended
25 Nov 2025
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • KLU156
  • Coartem
Record updated
4 November 2026

Who can take part

Age
2 months to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Male or female patients ≥ 10 kg of body weight
  • Microscopically confirmed diagnosis of uncomplicated P. falciparum malaria with an asexual P. falciparum parasitemia ≥ 1,000 and ≤ 200,000 parasites/µL at the time of pre-screening with or without other Plasmodium spp. co-infection
  • Axillary temperature ≥ 37.5 ºC or oral temperature ≥ 38.0 ºC or tympanic/rectal temperature ≥ 38.5 ºC; or history of fever during the previous 24 hours (at least documented verbally)
  • Negative pregnancy test for patients of childbearing potential
  • Signed informed consent was obtained before any assessment is performed; for minors, signed informed consent was obtained from parent/legal guardian. If the parent/legal guardian was unable to read and write, then a witnessed consent according to local ethical standards was permitted. Patients who were capable of providing assent, must have provided it along with parent/legal guardian consent or as per local ethical standards
  • The patient and/or their parent/legal guardian was able to understand and comply with protocol requirements, instructions and protocol-stated restrictions and was likely to complete the study as planned

Who cannot take part

  • Concurrent febrile illnesses (e.g., typhoid fever, known or suspected dengue fever, known COVID19)
  • Repeated vomiting (defined as > 3 times in the 24 hours prior to start of screening) or severe diarrhea (defined as > 3 watery stools in the 24 hours prior to start of screening)
  • Prior antimalarial therapy or antibiotics with antimalarial activity within minimum of their five plasma half-lives (or within 4 weeks of screening if half-life was unknown)
  • Any surgical or medical condition which might have significantly altered the absorption, distribution, metabolism, or excretion of drugs (e.g., Human immunodeficiency virus (HIV) patients on antiretroviral therapy (ART) or tuberculosis (TB) patients on treatment), or which may have jeopardized the patient in case of participation in the study
  • Anemia (hemoglobin level <7 g/dL)
  • Any of the following:; Aspartate Aminotransferase/ Alanine Aminotransferase (AST/ALT) > 3 x the upper limit of normal (ULN), regardless of the level of total bilirubin; Total bilirubin > 3 x ULN; Resting QT interval corrected by Fridericia's formula (QTcF) > 450 ms at screening
  • History or family history of long QT syndrome or sudden cardiac death, or any other clinical condition known to prolong the QTc interval, such as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe heart disease
  • Severe malnutrition. For patients ≥ 12 years: body mass index (BMI) < 16.0. For children < 12 years: less than 70% of median normalized WHO reference weight or very low mid-upper arm circumference (MUAC < 115 mm)
  • Signs and symptoms of severe malaria according to WHO 2015 (World Health Organization)
  • Clinically relevant abnormalities of electrolyte balance which required correction, e.g., hypokalemia, hypocalcemia or hypomagnesemia
  • Pregnant or nursing (lactating) patients

This trial has no sites in United States.

It has sites in 12 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study aimed to confirm the efficacy, safety and tolerability of KLU156, a fixed dose combination of ganaplacide (KAF156) and a solid dispersion formulation of lumefantrine (lumefantrine-SDF), when administered once daily for three days in adults and children ≥ 10 kg of body weight suffering from uncomplicated P. falciparum malaria (with or without other Plasmodium spp. co-infection).

Read full original descriptionShow less

In the extension phase, the safety, tolerability and efficacy of repeated treatment with KLU156 was assessed for a maximum of approximately 18 months in patients who did not experience early treatment failure (ETF), who did not experience any study treatment-related SAE (Serious Adverse Event) previously and who gave informed consent to participate in the Extension phase.

The 4 groups in the trial

  • KLU156Treatment being tested

    KLU156 once daily (QD) for 3 days under fed conditions (light meal).

  • CoartemExisting treatment, for comparison

    Coartem twice a day (BID) for 3 days under fed conditions.

  • KLU156 (Participants with <10 kg Body Weight)Treatment being tested

    KLU156 once daily (QD) for 3 days under fed conditions (light meal).

    Treatment: KLU156

  • Coartem (Participants with <10 kg Body Weight)Existing treatment, for comparison

    Coartem twice a day (BID) for 3 days under fed conditions.

    Treatment: Coartem

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized, Open-label, Multicenter Study to Compare Efficacy, Safety and Tolerability of KLU156 With Coartem® in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Adults and Children Followed by an Extension Phase With Repeated KLU156 Treatment
Publications
Record updated
4 November 2026